Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer

Incurable castration-resistant prostate cancer (CRPC) is driven by androgen receptor (AR) activation. Potent therapies that prevent AR signaling, such as Enzalutamide (ENZ), are mainstay treatments for CRPC; however patients eventually progress with ENZ resistant (ENZR) disease. In this study, we in...

Descripción completa

Detalles Bibliográficos
Autores principales: Shiota, Masaki, Bishop, Jennifer L., Takeuchi, Ario, Nip, Ka Mun, Cordonnier, Thomas, Beraldi, Eliana, Kuruma, Hidetoshi, Gleave, Martin E., Zoubeidi, Amina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496204/
https://www.ncbi.nlm.nih.gov/pubmed/25871401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496204/
https://www.ncbi.nlm.nih.gov/pubmed/25871401

Ejemplares similares